Y0001101
Interferon β-1a
European Pharmacopoeia (EP) Reference Standard
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Qualité
pharmaceutical primary standard
Famille d'API
interferon
Fabricant/nom de marque
EDQM
Application(s)
pharmaceutical (small molecule)
Format
neat
Conditions d'expédition
dry ice
Température de stockage
−70°C
Description générale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Conditionnement
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Autres remarques
Sales restrictions may apply.
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.
Si vous avez besoin d'assistance, veuillez contacter Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Richard A C Hughes et al.
The Cochrane database of systematic reviews, 2(2), CD008630-CD008630 (2013-03-02)
Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and this update in 2013. To review systematically the evidence from
N N Spirin et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(8), 27-33 (2012-10-26)
Authors have followed up 230 patients with multiple sclerosis treated with disease modifying drugs (DMD) using the data of the Multiple sclerosis register of the Yaroslavl oblast during 2009-2011. Original drugs and their generics registered in Russia are used. Patients
[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Gábor Széplaki et al.
Ideggyogyaszati szemle, 65(11-12), 369-376 (2013-01-08)
Fingolimod is a sphingosine-1 phosphate receptor modulator, which is effective in the treatment of severe relapsing-remitting form of multiple sclerosis. Once daily oral use of fingolimod decreased the annualized relapse rate, inflammatory brain lesion activity and the rate of brain
Alemtuzumab for multiple sclerosis: who and when to treat?
Till Sprenger et al.
Lancet (London, England), 380(9856), 1795-1797 (2012-11-07)
Hui Huang et al.
Journal of neuroimmunology, 258(1-2), 27-31 (2013-03-16)
The effect of pharmacologically relevant doses of interferon (IFN) β-1a on B-cell expression of B7.1 and B7.2 was investigated. Culture of peripheral blood mononuclear cells with IFN β-1a 100 IU/mL decreased B-cell expression of B7.1 and increased B7.2 expression. Interleukin-10
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique